BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9467483)

  • 1. A pilot study of intermittent androgen deprivation in advanced prostate cancer.
    Horwich A; Huddart RA; Gadd J; Boyd PJ; Hetherington JW; Whelan P; Dearnaley DP
    Br J Urol; 1998 Jan; 81(1):96-9. PubMed ID: 9467483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [